Pfizer price target lowered to $44 from $49 at Barclays
The Fly

Pfizer price target lowered to $44 from $49 at Barclays

Barclays analyst Carter Gould lowered the firm’s price target on Pfizer to $44 from $49 and keeps an Equal Weight rating on the shares post the Q4 results. The analyst reduced COVID-19 2023 sales expectations and says the greater risk is still to the downside with the end of the public health emergency on the horizon. The firm sees a difficult setup to underwrite rising demand versus current levels.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on PFE:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App